Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M.

J Clin Oncol. 2002 Jan 1;20(1):289-96.

PMID:
11773181
2.

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M.

J Clin Oncol. 2004 Feb 1;22(3):454-63.

PMID:
14752067
3.

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J.

J Clin Oncol. 1999 Aug;17(8):2530-40.

PMID:
10561319
4.

Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.

Yuasa T, Tsuchiya N, Urakami S, Horikawa Y, Narita S, Inoue T, Saito M, Yamamoto S, Yonese J, Fukui I, Nakano K, Takahashi S, Hatake K, Habuchi T.

BJU Int. 2012 May;109(9):1349-54. doi: 10.1111/j.1464-410X.2011.10534.x. Epub 2011 Aug 25.

5.

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA.

J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.

6.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators.

Lancet. 2007 Dec 22;370(9605):2103-11.

PMID:
18156031
7.

Predicting survival of patients with metastatic renal cell carcinoma.

Motzer RJ, Mazumdar M.

Urologe A. 2004 Sep;43 Suppl 3:S135-6.

PMID:
15148574
8.

Immunotherapy for advanced renal cell cancer.

Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425. Review. Update in: Cochrane Database Syst Rev. 2015;12:CD001425.

PMID:
15674877
9.

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial.

N Engl J Med. 2007 May 31;356(22):2271-81.

10.

Metastatic renal carcinoma comprehensive prognostic system.

Atzpodien J, Royston P, Wandert T, Reitz M; DGCIN -- German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group.

Br J Cancer. 2003 Feb 10;88(3):348-53.

11.

Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.

Kankuri M, Pelliniemi TT, Pyrhönen S, Nikkanen V, Helenius H, Salminen E.

Cancer. 2001 Aug 15;92(4):761-7.

PMID:
11550145
12.

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.

Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY.

Lancet Oncol. 2015 Mar;16(3):293-300. doi: 10.1016/S1470-2045(14)71222-7. Epub 2015 Feb 12.

PMID:
25681967
13.

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.

Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM.

Ann Oncol. 2011 May;22(5):1048-53. doi: 10.1093/annonc/mdq563. Epub 2010 Nov 29.

14.

Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.

Wagstaff J, Jones R, Hawkins R, Porfiri E, Pickering L, Bahl A, Brown J, Buchan S.

Ann Oncol. 2016 Jan;27(1):159-65. doi: 10.1093/annonc/mdv504. Epub 2015 Oct 21.

15.

Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus.

Amato RJ, Flaherty A, Zhang Y, Ouyang F, Mohlere V.

Urol Oncol. 2014 Apr;32(3):345-54. doi: 10.1016/j.urolonc.2013.09.008. Epub 2013 Dec 8.

PMID:
24321256
16.

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.

Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE.

J Clin Oncol. 1993 Jul;11(7):1368-75.

PMID:
8315435
17.

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, Baum CM, Kattan MW.

Cancer. 2008 Oct 1;113(7):1552-8. doi: 10.1002/cncr.23776.

18.

Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.

Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF.

Lancet. 2010 Feb 20;375(9715):641-8. doi: 10.1016/S0140-6736(09)61921-8. Epub 2010 Feb 10.

19.

Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.

Muriel C, Esteban E, Corral N, Fonseca PJ, Luque M, Berros JP, Fernández Y, Blay P, Fra J, Villanueva N, Sanmamed M, Pardo P, Izquierdo M, Vieitez JM, Estrada E, Lacave ÁJ.

Clin Transl Oncol. 2010 Aug;12(8):562-7. doi: 10.1007/s12094-010-0554-0.

PMID:
20709657
20.

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.

Halabi S, Rini B, Escudier B, Stadler WM, Small EJ.

Cancer. 2014 Jan 1;120(1):52-60. doi: 10.1002/cncr.28221. Epub 2013 Oct 8.

Supplemental Content

Support Center